Fresenius Medical (NYSE:FMS) Rating Change

In a research report issued to clients and investors on Thursday, 4 January, equity analysts at UBS’s equity research division increased Fresenius Medical (NYSE:FMS)’s stock from “Sell” to “Neutral”.

In spite of this stock rating upgrade NYSE:FMS is currently trading -0.11% lower at $46.92 as of 8:05 AM New York time. Fresenius Medical’s stock is 0% over the past 200 days. It has underperformed the Standard & Poor’s 500 index, which has surged 6.00% over the same time period.

According to data compiled by Thomson Reuters, Fresenius Medical (NYSE:FMS)’s stock is covered by 5 equity analysts across the Street, with 0 analysts giving it a Sell rating, 2 a Buy rating, while 4 consider it a Hold. The 12-month consensus target price for the stock is $45.9, which reflects an downside potential of 2.17% over the current price.

Fresenius Medical (NYSE:FMS) Profile

Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services.

Fresenius Medical (NYSE:FMS) traded down -0.11% on 4 January, hitting $46.92. A total of 36,328 shares of the company’s stock traded hands. This is down from average of 196,303 shares. Fresenius Medical has a 52 week low of $38.05 and a 52 week high of $50.22. The company has a market cap of $28.61 billion and a P/E ratio of 22.16.

Get the latest Fresenius Medical (NYSE:FMS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post How Will Fresenius Medical (NYSE:FMS) Stock React To UBS’s Upgrade to “Neutral” from “Sell”? appeared first on Octafinance.